Acute myeloid leukemia (AML) is a common hematopoietic malignancy characterized by the abnormal proliferation and differentiation of myeloid progenitor cells. The fusion gene AML1-ETO is the product of the t(8;21)(q22;q22) chromosomal translocation, which is associated with approximately 40% of cases with the M2 subtype of AML (8, 10, 30, 44) . The chimeric protein (AML1-ETO) contains the N terminus of the AML1 (RUNX1, CBF␣, PEBP2␣B) transcription factor and nearly the full-length ETO (MTG8) (39, 40) . The AML1 moiety of the AML1-ETO fusion protein has the Drosophila melanogaster protein runt homology domain, which is required for DNA binding and interaction with its heterodimerization partner, CBF␤, but which lacks the transcriptional activation domain of AML1 (35, 46, 61, 68, 70) . AML1 is a common target for chromosomal translocations and is involved in several other hematopoietic malignancies, such as the TEL-AML1 fusion observed in t (12;21) , which is involved in approximately 25% of childhood pre-B-cell acute lymphoblastic leukemias (14, 56, 59) ; AML1-MTG16 from t(16;21) with AML1 fused to ETO-related gene MTG16 (11) ; and AML1-EVI1 from t (3;21) in lymphoblast crises evolving from chronic myelogenous leukemia and in therapy-related AML (37, 42, 43) . These translocations point to a fundamental role of AML1 in hematopoiesis. Furthermore, analysis of AML1 knockout mice demonstrates that AML1 is a crucial factor for definitive hematopoiesis (48, 67) . The ETO moiety of AML1-ETO is able to recruit the nuclear receptor corepressor (N-CoR)-mammalian Sin3 (mSin3)-histone deacetylase-1 (HDAC1) complex (13, 32, 65) . ETO recruitment of the N-CoR-mSin3-HDAC1 complex leads to lower levels of histone acetylation and lessaccessible chromatin. Inhibition of HDAC has been shown to decrease ETO-mediated repression, inducing partial differentiation of AML1-ETO-positive Kasumi-1 cells (66) . Understanding how AML1 and its fusion proteins are involved in hematopoiesis and leukemogenesis will provide valuable insight into cell differentiation and cancer development.
Various attempts to develop a mouse model with AML1-ETO have so far failed to generate AML in adult mice. AML1-ETO heterozygous knockin mice died at the embryonic stage and displayed a block in definitive hematopoiesis (47, 75) . Inducible AML1-ETO-expressing transgenic mice were generated with a tetracycline-inducible system (55) . Unlike the knockin model mice, these mice are viable but fail to develop any malignancies despite strong expression of AML1-ETO in the bone marrow upon withdrawal of tetracycline. More recently, a promising murine model that mimics the t(8;21) chromosomal translocation through Cre/loxP-mediated recombination has been generated (5) . However, hematopoietic studies have yet to reveal any malignancies. These results suggested that AML1-ETO expression at a particular stage of hematopoietic cell development may be critical for its leukemogenic potential and that AML1-ETO-associated leukemogenesis may also require a secondary event or "hit" for AML1-ETOpositive cells to adopt leukemogenic behavior, including block of differentiation, dysregulation of proliferation, and/or reduction of apoptotic potential. Various cell lines have been estab-lished to study AML1 and AML1-ETO proteins. AML1 has been shown to promote cell cycle progression of myeloid progenitor cell line 32Dcl3 and to transform NIH 3T3 cells (25, 62) . Ectopic expression of AML1-ETO inhibits granulocytic differentiation of 32Dcl3 and L-G myeloid cell lines, monocytic differentiation of U937 cells, and erythroid differentiation of K562 and TF-1 cells (1, 13, 22, 24, 26, 71) . In addition, it has been reported that AML1-ETO expression decreases proliferation by up to threefold in interleukin-3-dependent L-G cells and induces cell-cycle arrest in 32Dcl3 and Ba/F3 cell lines (22, 29) . Furthermore, ectopic expression of AML1-ETO in NIH 3T3 cells has induced cell transformation (9) .
Here, we report the generation of inducible AML1-ETOexpressing cell line U937T-A/E using human myeloid cells to investigate the effect of AML1-ETO on hematopoiesis. Unlike most previously reported stable cell lines that continuously express AML1-ETO (1, 24, 58) , these cell lines present the advantage of not having been directly selected for AML1-ETO expression during their establishment. As such, these cell lines have not been preselected with particular features such as reduced apoptosic potential or enhanced proliferation prior to the analysis of AML1-ETO expression. In U937T-A/E cells, AML1-ETO is tightly regulated and strongly induced only upon tetracycline withdrawal at both mRNA and protein levels. Upon induction, the proliferation of AML1-ETO ϩ cells was severely reduced as the cells arrest in G 1 phase of the cell cycle. Eventually, most of these cells underwent apoptosis and exhibited decreased Bcl-2 expression. Enforced expression of Bcl-2 using retrovirus infection was able to significantly delay AML1-ETO-induced apoptosis, while the growth arrest remained. Furthermore, we also studied the effect of AML1-ETO on U937T cell differentiation. Induced expression of AML1-ETO in U937T-A/E cells significantly decreased the expression of CCAAT/enhancer binding protein ␣ (C/EBP␣) and altered the neutrophilic differentiation of U937T cells. These observations suggest a dichotomy of AML1-ETO properties in that the protein is able not only to block cell differentiation but also to induce cell cycle arrest, which eventually leads to apoptosis. We predict that the preleukemic AML1-ETO ϩ cell needs to overcome the growth arrest and/or the apoptotic potential of AML1-ETO prior to fulfilling its leukemogenic potential.
MATERIALS AND METHODS
Cell culture. Myeloid U937 and AML1-ETO-expressing Kasumi-1 cells were cultured in RPMI 1640 medium (GIBCO/BRL, Rockville, Md.) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, Utah) and 2 mM Lglutamine (GIBCO/BRL). Phoenix amphotropic cells (21) were maintained in Dulbecco's modified Eagle's medium (GIBCO/BRL) supplemented with 10% FBS, 2 mM L-glutamine, and 5 M ␤-mercaptoethanol (Fisher Scientific, Fair Lawn, N.J.). All cells were maintained in a 37°C incubator with 5% CO 2 . U937T cells are U937 cells stably transfected with a tet-VP16 fusion gene under the control of a tetracycline-inducible promoter; the cells were kindly provided by Gerald Grossveld (3, 15) . U937T cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 1 g of tetracycline (Sigma, St. Louis, Mo.)/ml, and 0.5 g of puromycin (Sigma)/ml.
Plasmid construction. The construction of pUHD-AML1/ETO was described previously (55) . The cDNAs for Bcl-2 (GenBank accession no. GI4557356) and for CDK4 (GenBank accession no. GI6753379) were subcloned into the EcoRI site of the MSCV-internal ribosome entry signal (IRES)-enhanced green fluorescent protein (EGFP) coding sequence (16) to form murine stem cell virus (MSCV)-Bcl-2-IRES-EGFP and MSCV-CDK4-IRES-EGFP (17) . The cDNA for c-myc (GenBank accession no. GI34820) was subcloned into HpaI of MSCV-IRES-EGFP to form MSCV-cMyc-IRES-EGFP. The BamHI and XhoI cDNA fragment for C/EBP␣ (GenBank accession no. GI4757971) was subcloned into BglII and XhoI of MSCV-IRES-EGFP to form MSCV-C/EBP␣-IRES-EGFP.
Establishment of U937T-A/E stable transformants. U937T cells were washed in RPMI 1640 medium without FBS and resuspended at 2 ϫ 10 7 cells/ml in 500 l of RPMI 1640 medium without FBS. Fifty micrograms of linearized pUHD-AML1/ETO (55) and 1 g of linearized pGK-Neo in 45 l of TE (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) were mixed with the cells, and the mixture was transferred to electroporation cuvettes with a 0.4-cm gap (Bio-Rad, Hercules, Calif.). Electroporations were performed using a Gene-Pulser II (Bio-Rad) at 300 V and 960 F. The samples were then transferred to complete RPMI 1640 medium containing 1 g of tetracycline and 0.5 g of puromycin/ml and incubated at 37°C in 5% CO 2 . Twenty-four hours later, G418 (GIBCO/BRL) was added at a concentration of 1 mg/ml. Positive polyclonal populations (pools) were identified based on Southern blot hybridization and on the induction of AML1-ETO expression following tetracycline withdrawal and were named U937T-A/E. Individual U937T-A/E clones were eventually isolated by limiting dilution and assayed for AML1-ETO inducibility. U937T-A/E cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, and 1 g of tetracycline, 0.5 g of puromycin, and 1 mg of G418/ml. Retrovirus infection of cell lines. For the production of retrovirus, Phoenix amphotropic cells were transfected with MSCV-Bcl-2-IRES-EGFP, MSCV-CDK4-IRES-EGFP, MSCV-cMyc-IRES-EGFP, MSCV-C/EBP␣-IRES-EGFP, or MSCV-IRES-EGFP vector by calcium phosphate precipitation (21) . Retrovirus supernatants were harvested 48 h after transfection, filtered through 0.45-m-pore-size filters, and stored at Ϫ80°C. Filtered supernatant was used to infect U937T and U937T-A/E cells in the presence of 8 g of Polybrene (Sigma)/ml. The infected cells were then centrifuged at 700 ϫ g for 1 h at room temperature and incubated at 37°C in 5% CO 2 . The medium was changed 24 h after virus infection. Cells infected with the various MSCV-IRES-EGFP constructs were identified on the basis of green fluorescence.
Northern blot analysis. Total RNA was isolated from the U937T-A/E cell lines by extraction with guanidine isothiocyanate and centrifugation through cesium chloride, and Northern blot analysis was performed as described previously (55, 76) . Blots were exposed to MR X-ray films (Kodak, Rochester, N.Y.).
RPA. The RNA samples were hybridized with the hAPO-2c (BD Pharmingen, La Jolla, Calif.) set of probes against the main members of the Bcl-2 family. The RNase protection assay (RPA) was performed using the RiboQuant RPA starter package according to the manufacturer's instructions (BD Pharmingen). The level of modulation of Bcl-2 was determined by using a Storm phosphorimager (Molecular Dynamics, Sunnyvale, Calif.) and Image software (Scion Corporation, Frederick, Md.).
Transient transfection assays. Electroporation was performed with a Bio-Rad Gene-Pulser II (230 V, 975 F). U937T cells were transfected with 25 g of total DNA, including 13 g of pXP1 (GenBank accession no. GI3929277) or 20 g of pBcl2-luc (equimolarity) or 20 g of MDR-1-luc (63) or 1.4 g of pCMV5 (empty expression vector; GenBank accession no. GI7542546) or 2 or 4 g of pCMV5-AML1-ETO and 100 ng of pRL-Null (GenBank accession no. GI7638455) to normalize transfection efficiency. Alternatively, U937T and U937T-A/E cells were induced for 12 h prior to transfection. Transfected cells were harvested 24 h after electroporation, and luciferase activity was measured using the dual-luciferase reporter assay system (Promega).
Western blot analysis. Cells were washed in phosphate-buffered saline (PBS) and resuspended in Laemmli buffer (1% sodium dodecyl sulfate [SDS], 0.1275 M Tris-HCl [pH 6.8], 1% ␤-mercaptoethanol). The protein concentration of the supernatant was assessed using the Bio-Rad protein assay according to the manufacturer's instructions. Following SDS-polyacrylamide gel electrophoresis (PAGE), proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad) using a Mini-Trans-Blot cell (Bio-Rad). The blot was then blocked in 5% dry milk in Tris-buffered saline with 0.1% Tween 20. The blot was then incubated with a 1:1,000 dilution of rabbit anti-ETO antibody (a gift from Scott Hiebert), a 1:1,000 dilution of rabbit anti-human Bcl-2 antibody (a gift from John Reed), and a 1:5,000 dilution of mouse anti-human ␤-actin (AC15) (Sigma). The blot was then incubated with appropriate secondary antibodies conjugated to horseradish peroxidase (Amersham Pharmacia Biotech, Piscataway, N.J.). The blot was developed using a chemiluminescent substrate (Renaissance; NEN, Boston, Mass.) and exposed to MR X-ray film (Kodak). In all Western blot analyses, ␤-actin or Coomassie staining of the SDS-PAGE gel after transfer was used as a loading control.
Analysis of cell proliferation, differentiation, morphology, and cell cycle. For the induction of tetracycline-controlled AML1-ETO, the cells were washed three times in 50 ml of PBS and seeded at 10 5 cells/ml in the maintenance medium in the presence of the desired tetracycline concentration. The viability of the cells was assessed daily by trypan blue exclusion. The cells were induced to differentiate by adding 65 nM phorbol 12-myristate 13-acetate (TPA) (Sigma) to the culture medium 24 h after tetracycline withdrawal. Morphology was determined by Wright-Giemsa staining of air-dried cytospin preparations. Cell cycle distribution was evaluated by flow cytometry analysis of propidium iodide-stained nuclei (41) . A minimum of 10 4 cells were analyzed using a FACSCalibur (BD Immunocytometry, San Jose, Calif.). The cell cycle distribution was assessed using ModFit LT software (Verity Software House, Topsham, Maine) Detection of apoptosis. Apoptotic cells were identified by double staining with acridine orange (100 g/ml; Sigma) and ethidium bromide (100 g/ml; Sigma) (36) . The level of apoptosis was also assessed by flow cytometry of cells stained with annexin V-phycoerythrin (PE) and 7-aminoactinomycin D (7-AAD; BD Pharmingen). The cells (10 5 
RESULTS

Establishment of myeloid cell lines with inducible expression of AML1-ETO.
To study the effect of AML1-ETO on the growth, survival, and differentiation of myeloid cells, we made inducible AML1-ETO-expressing U937T cell lines. The AML1-ETO cDNA was inserted into tetracycline-responsive expression vector pUHD10-3 to form pUHD-AML1/ETO (55) . pUHD-AML1/ETO was introduced into the U937T cells, which contain stably transfected pUHD-tTA (a tetracyclineresponsive transcription activator [tTA], whose expression is under the control of tetracycline) to establish the inducible cell lines (3). In principle, in the presence of tetracycline, the expression of tTA and AML1-ETO should be extremely low; in the absence of tetracycline, tTA activates its own promoter to produce more tTA and also activates AML1-ETO expression. Forty-eight pools of U937T cells stably transfected with pUHD-AML1/ETO were confirmed by Southern blot hybridization. Cells were cultured in the presence or absence of tetracycline to test the inducibility of AML1-ETO expression. Northern blot hybridization using RNA harvested from these cultures demonstrated that only two pools (pools 18 and 48) of U937T-A/E cells were inducible for AML1-ETO expression upon withdrawal of tetracycline (Fig. 1A) . All the other pools did not show AML1-ETO expression in either the presence or absence of tetracycline (data not shown). Pools 18 and 48 showed very tight control of AML1-ETO expression. Furthermore, the inducible up-regulation of AML1-ETO was also demonstrated at the protein level in Western blot analysis (Fig.  1B) .
Inducible expression of AML1-ETO reduces proliferation and affects the viability of U937T-A/E cells. We first tested the effect of AML1-ETO expression on cell proliferation. U937T-A/E pool 18 and 48 cells and their parental cell line, U937T, were cultured in the presence of tetracycline (no induction of AML-ETO expression) and in the absence of tetracycline (induction of AML1-ETO expression). AML1-ETO transcripts were clearly detectable 24 h after the induction and reached a maximum at 48 h postinduction (Fig. 2A) . The growth curve showed a significant reduction of cell growth when AML1-ETO was expressed. This delay was initiated 2 days after induction and continued, with the proliferation being substantially reduced compared to that for uninduced cells (Fig. 2B and C). The proliferation of the parental U937T cells was the same in the presence and the absence of tetracycline, indicating that the effect was due solely to the expression of AML1-ETO. Besides the reduction of the proliferative potential of the U937T-A/E pool 18 and 48 cells, a clear reduction of the viability of AML1-ETO-expressing cells was observed 3 days after induction. To determine how the expression of AML1-ETO affected the cell cycle, we analyzed by flow cytometry the DNA content of propidium iodide-stained nuclei from induced cells using pool 48 cells and clones U937T-A/E 48-5 and 48-9 (no significant differences between the different populations were detected; data from pool 48 are represented in Fig. 3) . After 57 h of AML1-ETO induction, the proportion of cells in S phase decreased from 45 to 22% and the percentage of cells in G 0 /G 1 phase increased from 45 to 69% (Fig. 3) , indicating the blockage of the G 1 -to-S phase transition. At this time point, no cells with a sub-G 1 DNA content were detected. However, by 81 h, 13% of cells displayed a sub-G 1 DNA content, and the proportion rose to 33% after 100 h. Nicoletti et al. (41) have shown that a cell with hypoploid content is an indication of the cell becoming apoptotic. As shown in Fig. 4 , dual acridine orange and ethidium bromide staining of the AML1-ETO-induced U937T-A/E pool 48 cells showed an accumulation of cells with chromatin condensation and fragmentation, which confirmed that AML1-ETO-induced cell death was caused by apoptosis. Furthermore, terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling assays to detect double-strand DNA breaks also demonstrated apoptotic events in AML1-ETO-expressing cells (data not shown) (12) .
AML1-ETO-induced apoptosis is associated with the decrease of Bcl-2 expression.
To further analyze the molecular components involved in the induction of apoptosis in U937T-A/E cells, we examined the RNA expression pattern of the members of the Bcl-2 family by RPA (Fig. 5A ). Three days after withdrawal of tetracycline to induce AML1-ETO expression, the amounts of Bcl-2 transcripts were significantly reduced in both U937T-A/E pool 18 and 48 cells. Densitometry analysis showed a 10-fold difference in Bcl-2 RNA levels between AML1-ETO-induced cells and uninduced cells, compared to the difference for housekeeping gene transcripts. Some of the other members of antiapoptosis or proapoptosis genes of the Bcl-2 gene family also showed different levels of expression, but the difference was not as dramatic as that for the Bcl-2 gene. Furthermore, a reduction of Bcl-2 at the protein level was also observed by Western blotting (Fig. 5B) .
Bcl-2 is an important antiapoptosis factor (7, 54) . Bcl-2 expression has also been reported to affect cell cycle progression (4, 33, 49) . Therefore, to determine whether the suppression of Bcl-2 expression significantly contributed to the alteration of cell proliferation and apoptosis in induced U937T-A/E cells, Bcl-2 was ectopically expressed in U937T and U937T-A/E cells using an MSCV-Bcl2-IRES-EGFP retrovirus construct. Viral particles prepared from Phoenix amphotropic cells were used to infect U937T and U937T-A/E cells. EGFP expressed through the IRES was used to monitor ectopic Bcl-2-expressing cells. EGFP) and Bcl-2-expressing virus (MSCV-Bcl-2-IRES-EGFP) remained stable at approximately 20% for more than 1 month in both U937T and U937T-A/E pool 48 cells in the presence of tetracycline as determined by flow cytometry (data not shown). Upon induction of AML1-ETO expression, the proportion of viable EGFP ϩ U937T-A/E cells remained steady at 22% for 2 days before progressively increasing to 47% 5 days after induction in U937T-A/E cells infected with MSCV-Bcl-2-IRES-EGFP, whereas the proportion of viable EGFP ϩ cells remained constant in U937T cells and U937T-A/E cells infected with vector control MSCV-IRES-EGFP (Fig. 6A) . Although the proportion of EGFP ϩ Bcl-2 ϩ cells increased to up to one-half of the viable U937T-A/E cells, the overexpression of Bcl-2 was unable to restore the proliferation of those cells and to suppress apoptosis, as all cells eventually underwent apoptosis. However, the increase of Bcl-2-positive cells in the culture indicated that Bcl-2 expression was able to delay apoptosis. To better understand the effect of Bcl-2, the cells infected with MSCV-Bcl-2-IRES-EGFP were sorted by flow cytometry on the basis of the EGFP expression. Later, the cell cycle distributions of both EGFP ϩ and EGFP Ϫ cells were analyzed upon AML1-ETO induction. As seen previously in the mix population, the ectopic expression of Bcl-2 dramatically reduced apoptosis over a period of 96 h (Fig. 6C) . However, the ectopic expression of Bcl-2 was unable to prevent the FIG. 4 . Inducible expression of AML1-ETO leads to apoptosis in U937T-A/E cells. Detection of apoptotic cells was performed by acridine orange and ethidium bromide double staining. U937T-A/E cells were maintained for 72 h in the medium either containing 1 g of tetracycline/ml (A) or not containing tetracycline (B). Both live and dead cells take up acridine orange. Acridine orange intercalates into DNA and RNA, making the former appear green while the latter stains red. Thus a viable cell has bright green chromatin in its nucleus and red-orange cytoplasm. Ethidium bromide is only taken up by nonviable cells. Ethidium bromide intercalates into DNA, making it appear orange, but binds only weakly to RNA, which may appear slightly red. Thus a dead cell has bright orange chromatin (the ethidium overwhelms the acridine) and its cytoplasm, if it has any contents remaining, appears dark red. Cells that have undergone necrosis have the fluorescent features of nonviable cells but do not have apoptotic nuclear morphology. VN, viable cells with normal nuclei (bright green chromatin with organized structure); VA, viable cells with apoptotic nuclei (bright green chromatin which is highly condensed or fragmented); NVA, nonviable cells with apoptotic nuclei (bright orange chromatin which is highly condensed or fragmented). (Fig. 6B ). We also confirmed that the level of ectopic Bcl-2 expression was essentially unchanged for the length of experiments, whereas AML1-ETO was significantly up-regulated by 72 h in the absence of tetracycline (Fig. 6D) .
The effect of AML1-ETO on Bcl-2 expression has been studied previously. Klampfler et al. reported the transactivation of the Bcl-2 promoter by AML1-ETO via an AML1 binding consensus sequence (23) . Two cell lines derived from t(8; 21) leukemia patient cells showed higher expression of Bcl-2 (23, 24) . However, studies using 29 (57) and 17 (2) primary t(8;21) leukemia patient samples indicated that Bcl-2 expression was generally down-regulated compared to that for nonleukemic or non-t(8;21) AML samples. Therefore, we performed studies to determine whether the down-regulation of Bcl-2 was the direct effect of AML1-ETO on a 3.7-kb Bcl-2 promoter in U937T and U937T-A/E cells using transient transfection assays (Fig. 7A and B) . The data indicated that AML1-ETO down-regulation of Bcl-2 expression in this particular cell line was not a direct effect of AML1-ETO on the 3.7-kb Bcl-2 gene upstream regulatory element. To ensure the accuracy of the data presented, as the current results did not agree with previous studies (23), we assessed whether AML1-ETO was also able to repress the expression of the (Ϫ137 to ϩ30) multidrug resistance 1 (MDR-1) promoter as previously reported (31) . The data confirmed that AML1-ETO represses transcription of the MDR-1 promoter in U937T (Fig. 7C) .
AML1-ETO alters myeloid differentiation. The effect of AML1-ETO on U937T cell differentiation was also studied with these inducible AML1-ETO-expressing cells. Parental U937T cells and U937T-A/E cells were treated with TPA. Interestingly the differentiation patterns of U937 and U937T cells were different, as U937 cells treated with TPA rapidly assumed (24 h) a macrophage-like morphology (data not shown) whereas U937T and uninduced U937T-A/E pool 48 cells slowly displayed "doughnut-shaped" nuclei characteristic of granulocytes upon TPA treatment (Fig. 8A) . In contrast, the surviving fraction of induced U937T-A/E cells treated with TPA did not exhibit doughnut-shaped nuclei. Nonetheless, the cells displayed some signs of maturation, with cytoplasm larger than that of untreated samples, which displayed lymphoblastlike morphologies. As in previous studies, the effects of AML1-ETO on differentiation were further analyzed by flow cytometry (13, 28) , which revealed a clear increase of the cell surface differentiation markers CD11b and CD18 upon TPA treatment ( Fig. 8B ; from CD11b low and CD18 low to CD11b high and CD18 high ). The increase in the CD11b and CD18 cell surface markers precedes the occurrence of the doughnut-shaped nuclei mentioned previously. However, the induction of AML1-ETO significantly reduced the differentiation of U937T-A/E cells. These cells lost their original lymphoblast-like morphology without displaying granulocytic morphology (Fig. 8A) and exhibited a block of differentiation at an early stage ( Fig. 8B ; CD11b low and CD18 low ).
C/EBP␣ is down-regulated upon AML1-ETO expression.
The alteration of granulocytic differentiation suggested that AML1-ETO expression might affect certain critical factors involved in myeloid lineage commitment. Since C/EBP␣ and C/EBPε are important transcription factors for granulocytic cell differentiation, we hypothesized that down-regulation of their expression may be involved in the block of granulocytic differentiation (53, (72) (73) (74) 78) . Therefore, Northern blot analysis was used to study the expression of C/EBP␣ and C/EBPε. C/EBPε expression is barely detectable in uninduced U937T-A/E cells. Upon induction, no obvious change of C/EBPε was detected (data not shown). C/EBP␣ was expressed at high levels in U937 and U937T parental cells and uninduced U937T-A/E cells (Fig. 9A) . Upon induction of AML1-ETO expression, C/EBP␣ was considerably down-regulated (Fig.  9A) . In a time course analysis, the decrease of C/EBP␣ transcripts showed a tight correlation with the induced expression of AML1-ETO (Fig. 9B) . Furthermore, the expression of two cell cycle-related genes, cdk4 and c-myc, were also down-regulated (Fig. 9B) . The effects of TPA treatment on the level of C/EBP␣ were also assayed (Fig. 9C) . Treatment with TPA did not alter the down-regulation of C/EBP␣ by AML1-ETO.
To determine whether the down-regulation of C/EBP␣ was a central part of the inhibition of differentiation by AML1-ETO, C/EBP␣ was ectopically expressed in U937T and U937T-A/E using an MSCV-C/EBP␣-IRES-EGFP retrovirus construct. Following retrovirus infection, the proportion of EGFPpositive cells decreased rapidly from 30 to 10% within 5 days FIG. 7 . Transactivation analysis of the Bcl-2 promoter with AML1-ETO. (A) U937T and U937T-A/E cells were transfected with either promoterless firefly luciferase reporter pXP1 or the 3.7-kb Bcl-2 gene upstream sequence-firefly luciferase reporter pBcl2-luc after they had been cultured in the absence or presence of tetracycline for 12 h. The pRL-Null Renilla luciferase construct was cotransfected to normalize transfection efficiency. (B) U937T cells were transfected with pXP1 or pBcl2-luc and various amounts of pCMV5 or pCMV5-AML1-ETO, along with pRL-Null to normalize transfection efficiency. The activity of the promoter was calculated as the ratio of the firefly luciferase activity and the Renilla luciferase activity. The transactivation was calculated as the ratio between pXP1 and pBcl2-luc with 0, 2, and 4 g of pCMV5-AML1-ETO, assuming a value of 1 for each in the presence of pXP1. (C) U937T cells were transfected with MDR-1-luc and various amounts of pCMV5 or pCMV5-AML1-ETO, along with pRLNull to normalize transfection efficiency. The activity of the promoter was calculated as the ratio of the firefly luciferase activity and the Renilla luciferase activity. The transactivation was calculated as the ratio between 0 g and 2 or 4 g of pCMV5-AML1-ETO. The results are the means of three independent experiments (standard errors of the means are shown when measurable). after the infection (data not shown). The reduction is the result of a reduced proliferation caused by the spontaneous differentiation of both U937T and uninduced U937T-A/E due to C/EBP␣ expression as determined by CD11b staining (Fig. 10) . Interestingly, the induction of AML1-ETO halted the differentiation induced by ectopic C/EBP␣ as determined by CD11b staining (Fig. 10) . The addition of TPA in conjunction with the ectopic expression of C/EBP␣ was only able to cause a small increase of CD11b-positive cells. Even in the presence of TPA, the ectopic expression of C/EBP␣ was unable to antagonize the effect of AML1-ETO.
DISCUSSION
To investigate the role of AML1-ETO in leukemogenesis, we examined the biological properties of the AML1-ETO fusion protein by inducible expression in U937T cells. The most interesting finding from this study is that AML1-ETO plays antagonistic roles regarding cancer development. AML1-ETO expression favors leukemogenesis by blocking cell differentiation associated with the decrease of C/EBP␣ protein level and opposes leukemogenesis by blocking cell proliferation, leading to apoptosis.
AML1-ETO blocks granulocytic differentiation and downregulates C/EBP␣ expression. The treatment of U937T and uninduced U937T-A/E cells with TPA leads to progressive granulocytic maturation associated with an increased expression of cell surface markers CD11b and CD18. This differentiation was significantly reduced in AML1-ETO ϩ cells. This altered differentiation potential is correlated with the downregulation of C/EBP␣ upon induction of AML1-ETO (Fig. 9) . C/EBP␣ is the founding member of the C/EBP transcription factor family, regulating many genes involved in myeloid lineage commitment and differentiation (6, 19, 20, 27, 45, 52, 60, 69, 77; A. Khanna-Gupta, T. Zibello, C. Simkevich, A. G. Rosmarin, and N. Berliner, Abstr. Third Int. Meet. Mol. Aspects Myeloid Stem Cell Dev., abstr. 10, 1999) . C/EBP␣ is up-regulated during granulocytic differentiation, and overexpression of C/EBP␣ in U937 cells leads to granulocytic differentiation (53) . Furthermore, C/EBP␣-deficient mice lack mature granulocytes, indicating a critical role in granulocytic differentiation (78) . Interestingly, C/EBP␣ is consistently expressed at much lower level in AML M2 subtype patients with t(8;21) translocation than in patients with other subtypes of AML (50) . Moreover, dominant-negative mutations of C/EBP␣ leading to a failure to induce granulocytic differentiation have been detected in 16% of AML M2 patients without t(8;21) translocation, emphasizing the important contribution of C/EBP␣ to AML leukemogenesis (51) .
Although U937 cells constitutively express C/EBP␣, U937T and uninduced U937T-A/E cells express markedly higher levels of C/EBP␣ mRNA than the parental U937 cells. This difference may be reflected in the higher propensity for granulocytic differentiation of the U937T cells.
The ectopic expression of C/EBP␣ causes a rapid up-regu- lation of the CD11b cell surface marker in both U937T and uninduced U937T-A/E cells. However, the induction of AML1-ETO prevents the CD11b up-regulation induced by C/EBP␣ in U937T-A/E cells, suggesting that the down-regulation of C/EBP␣ probably contributes to the inhibition of differentiation but is not enough to fully explain this inhibition. In contrast, ectopic expression of C/EBP␣ in Kasumi-1 cells leads to granulocytic differentiation (50) . One explanation could be that the cell cycle arrest caused by the induction of AML1-ETO blocks the differentiation despite the presence of C/EBP␣, in contrast to what is found for Kasumi-1 cells. Alternatively, Westendorf et al. have previously demonstrated that AML1-ETO physically interacts with C/EBP␣, abrogates C/EBP␣-dependent transcription, and ultimately blocks granulocytic differentiation (71) . C/EBP␣ activates its own promoter through an upstream stimulatory factor (USF) binding site (63) . It has been shown that AML1-ETO decreases C/EBP␣ promoter activity also via a USF binding site (50) . Therefore, it is possible that AML1-ETO prevents the autoactivation of the C/EBP␣ promoter by USF through proteinprotein interaction with C/EBP␣ Shimizu et al. (58) reported recently that AML1-ETO upregulates C/EBPε expression without identifying an AML1 binding site in the C/EBPε promoter, suggesting the existence of additional steps between the expression of AML1-ETO and the up-regulation of C/EBPε. Interestingly, the expression of C/EBPε was also reported in cell lines derived from AML M2 patients but not in other hematopoietic cell lines such as U937.
In the present studies, we did not observe any significant modulation of C/EBPε expression. The difference in C/EBPε expression between AML M2-derived cell lines and the present model could be reconciled by the presence or absence of a yet to be identified factor that would cooperate with AML1-ETO to induce the expression of C/EBPε.
AML1-ETO blocks cell proliferation by inducing cell arrest in G 0 /G 1 . The induction of AML1-ETO in U937T-A/E cells causes a progressive cell cycle arrest in G 0 /G 1 phase. This growth arrest coincides with the down-regulation of c-myc and CDK4 (Fig. 9B) . Lou et al. have recently reported that the tamoxifen-inducible fusion protein KRAB-AML1-ER prolongs G 1 phase (29) , possibly through the down-regulation of CDK4. Furthermore, Hermeking et al. have also identified CDK4 as a transcriptional target of c-myc (18) . These authors suggest that the ability of c-myc to promote cell cycle reentry is in part due to its ability to directly induce the transcription of CDK4. We assume that the down-regulation of c-myc causes the down-regulation of CDK4, thereby contributing to blocking the cell cycle. Upon induction of AML1-ETO, the expression pattern of CDK4 closely matches that of c-myc expression, as transcription culminates 12 h after induction before decreasing to its lowest level by 48 h (highest level of AML1-ETO; Fig.  9B ). The overexpression of CDK4 or c-myc in U937T-A/E cells using the MSCV-CDK4-IRES-EGFP or MSCV-cMyc-IRES-EGFP retrovirus construct was not able to prevent the growth arrest and apoptosis caused by the conditional expression of AML1-ETO in U937T-A/E cells (data not shown). Interestingly, the down-regulation of C/EBP␣ may actually antagonize growth arrest, as C/EBP␣ has been reported in hepatocytes to increase the level of p21/WAF-1, thereby causing growth arrest (64) . Therefore, we hypothesize that AML1-ETO deregulates the expression of a yet to be identified factor that may be responsible for the down-regulation of both c-myc and CDK4. However, c-myc and CDK4 may not be the only targets of this putative factor to provoke cell cycle arrest of AML1-ETO ϩ cells. If such a factor were identified, we predict that the separation of its function with those of AML1-ETO would potentially unlock the growth arrest and contribute significantly to the leukemogenic process. Another interesting question raised by these results is whether DNA binding is required for AML1-ETO to induce cell cycle arrest or whether the growth arrest occurs through protein-protein interaction possibly mediated through the ETO moiety as reported recently by Melnick et al. (34) .
AML1-ETO induces apoptosis and reduces Bcl-2 level. Eventually, the induction of AML1-ETO results in the onset of apoptosis in U937T-A/E cells. We also report the down-regulation of Bcl-2 at the RNA and protein levels following induction of AML1-ETO, suggesting that down-regulation of Bcl-2 contributed to the reduced survival of U937T-A/E cells. However, ectopic expression of Bcl-2 delays apoptosis without preventing AML1-ETO-induced G 1 /G 0 arrest. Moreover, the inability of Bcl-2, which acts essentially downstream of the cell cycle, to prevent cell cycle arrest despite delaying apoptosis suggests that Bcl-2 is not a direct target of AML1-ETO (Fig.  6) . Therefore, the AML1-ETO ϩ cells may initiate apoptosis through their inability to overcome cell cycle arrest.
Two groups have reported that t(8;21)-bearing de novo leukemia cells express, in general, lower levels of Bcl-2 protein than normal bone marrow, other non-t(8;21) AML samples, and Kasumi-1 and SKNO-1 cells (2, 23, 24, 57). Klampfer et al. report that AML1-ETO is able to transactivate the Bcl-2 promoter via a consensus AML1 binding sequence (23) . As our results indicate that the induction of AML1-ETO results in the down-regulation of Bcl-2, we reexamined the effects of transient expression or induction of AML1-ETO in the specific context of U937T and U937T-A/E cells using the same Bcl-2 promoter fragment (Fig. 7) (23, 38) . AML1-ETO does not transactivate the Bcl-2 promoter in U937T cells, indicating a cell type-specific effect of AML1-ETO on the regulation of the Bcl-2 promoter. Furthermore, the delay in the onset of apoptosis also reinforces the idea that Bcl-2 is not a target of AML1-ETO in U937T-A/E cells.
In summary, our studies with inducible cells indicate that expression of AML1-ETO blocks cell differentiation and proliferation and consequently induces apoptosis. The reduced granulocytic maturation in AML1-ETO ϩ cells correlates with the down-regulation of C/EBP␣. Modulation of C/EBP␣ is critical for the commitment to the granulocytic lineage (53, 78) . The low level of C/EBP␣ reported in t(8;21) patients also suggests that the reduction of C/EBP␣ is central for blocking AML cells at the M2 differentiation stage (50) . In view of the effects of AML1-ETO on the regulation of C/EBP␣ function, further studies are required to clarify whether overexpression of C/EBP␣ in t(8;21) patients is enough to induce the maturation of the leukemic cells and improve their clinical outcome.
In addition to blocking cell differentiation, AML1-ETO also blocks proliferation by inducing cell cycle arrest. This finding is further supported by the data from AML1-ETO knockin mice and the tetracycline-inducible mouse model. In previous studies, the effect of AML1-ETO on the cell cycle or apoptosis in the bone marrow of tetracycline-inducible AML1-ETO mice could not be determined. However, the new perspective offered by our findings now supports the negative effect of AML1-ETO on cell proliferation and survival observed in primary bone marrow and CFU-granulocyte-macrophage (GM) assays. First, AML1-ETO knockin mice died in midgestation without the development of definitive hematopoietic cells, raising the possibility of AML1-ETO expression blocking the proliferation of hematopoietic precursor cells (47, 75) . Second, the infection of adult murine bone marrow with MSCV-AML1-ETOneo leads to a lower number of colonies than with the retrovirus vector control (75) . Last, AML1-ETO-inducible transgenic mice, although viable, do not develop leukemia, but induction of AML1-ETO in the bone marrow of those mice exerts a detrimental effect on CFU GM number and size as well as blocking cell differentiation (55) . The homeostasis in vivo and the high concentration of growth factors used in in vitro CFU assays may contribute to a decrease of AML1-ETO effects compared to those reported in U937T-A/E cells. Both Yergeau et al. and Okuda et al. followed the same experimental procedure for the CFU assay, including the use of fetal liver cells from the same developmental stage, for assessing the outcome of AML1-ETO expression. Nonetheless, the different origins of cells used to establish the AML1-ETO knockin mice could be another source of discrepancies between both models. While Okuda et al. reports the presence of dysplastic hematopoietic colonies with high replating efficiency, Yergeau et al. did not detect any dysplastic replating colonies (47, 75) . In fact, no colonies were detected in the fetal liver culture. Additional mutations could reconcile the observed differences.
If growth arrest and apoptosis are general features associated with the expression of AML1-ETO, we predict that the putative link that unites them to AML1-ETO must also be severed prior to the occurrence of the t(8;21) translocation to allow the survival and expansion of the preleukemic cells. Inhibition of proliferation or apoptosis would not be favorable to the propagation of cells harboring the t(8;21) translocation. Therefore, we favor the hypothesis that other oncogenic events promoting proliferation or cell survival are necessary for the development of t(8;21) AML.
